Autres langues Provectus Biopharmaceuticals, Inc.

Actions

PVCT

US74373P1084

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:54:18 26/08/2026			Varia. 5j.	Varia. 1 janv.
0,0589 ^USD	-2,34 %		+1,20 %	+5,37 %

13/08	Provectus Biopharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
07/07	Provectus Biopharmaceuticals, Inc. met en avant une étude évaluée par les pairs démontrant les effets mécanistes opposés du Rose Bengale sodique à une dose identique	CI

Autres langues

13/08	Provectus: Q2 Earnings Snapshot
13/08	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
22/07	VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
07/07	Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose
07/07	Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
30/06	Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
25/06	Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
25/06	Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10
08/06	Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
18/05	Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study
18/05	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
18/05	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
14/05	Provectus: Q1 Earnings Snapshot
14/05	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
04/05	Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
04/05	Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026
21/04	Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
02/04	Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing
02/04	Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
26/03	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
26/03	Provectus: Q4 Earnings Snapshot
26/03	Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
13/11	Provectus: Q3 Earnings Snapshot
13/11	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
10/10/25	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants, University of Calgary Research Highlights Novel STING-Pathway Activation